1. USBC, Inc. changed its name from Know Labs, Inc. 2. The stock will trade under the new ticker symbol 'USBC' from August 15, 2025. 3. A $125M acquisition by Goldeneye 1995 LLC occurred on August 6, 2025. 4. USBC focuses on developing a U.S.-dollar denominated digital deposit token. 5. The company employs a bitcoin treasury strategy for development purposes.

1. Telos Corporation announced Q2 2025 financial results today. 2. Live webcast discussion is scheduled for August 11, 2025. 3. Telos provides cybersecurity and cloud security solutions globally. 4. The company focuses on security for highly sensitive organizations. 5. Presentation materials are available on the investor relations website.

1. WEBTOON's Q2 revenue reached $348.3 million, up 8.5% year-over-year. 2. Adjusted EBITDA of $9.7 million reflects operational shifts, lower expenses. 3. Cash reserves stand at $581.5 million with no debt reported. 4. Disney collaboration will enhance growth opportunities in IP adaptations. 5. Strong revenue outlook for Q3 2025 expected between $380-$390 million.

1. Gevo posted a positive net income of $2.1 million in Q2 2025. 2. Adjusted EBITDA reached $17 million, showcasing financial stability. 3. Carbon credit sales began, creating a new revenue stream. 4. Projected long-term CDR credit sales could exceed $30 million annually. 5. Gevo targets growth in sustainable aviation fuel production capacity.

1. PAPZIMEOS is the first FDA-approved therapy for RRP in adults. 2. The approval eliminates the need for further confirmatory clinical trials. 3. RRP affects approximately 27,000 adult patients in the U.S. 4. PAPZIMEOS aims to target the root cause of RRP effectively. 5. Precigen will commence promotion and support programs for PAPZIMEOS.